<DOC>
	<DOCNO>NCT02209389</DOCNO>
	<brief_summary>The OctavaPink test indicate adjunct mammography breast cancer screen asymptomatic woman screen diagnostic mammography finding normal benign ( BIRADS assessment category 1 2 ) breast tissue dense ( BIRADS composition/density 3 4 ) . The device intend increase breast cancer detection describe patient population . Based upon result OctavaPink , patient evaluate physician .</brief_summary>
	<brief_title>OctavaPink Women With Dense Breast After Negative Mammography</brief_title>
	<detailed_description>This multicenter , prospective study contain 3 part : Part 1 consist Part 1A ( optimization/training ) Part 1B ( evaluation/testing ) follow : Part 1A optimize OctavaPink test woman dense breast tissue , affect treatment participant . Part 1A internal part do EventusDx statistical evaluation need . Objectives : To optimize OctavaPink test , target ≥95 % specificity ≥70 % sensitivity . Part 1B ass property OctavaPink test use case control obtain via criterion Part 1A . The sensitivity specificity OctavaPink test must confirm sufficiently high sample EventusDx blind case/control status use test affect clinical management patient . Objectives : ( ) To obtain sensitivity estimate ≥60 % 95 % CI low limit ≥50 % whole group cancer case ( DCIS , IDC ILC ) ; also obtain sensitivity estimate property subset case invasive cancer ( IDC ILC ) . ( ii ) To obtain specificity estimate ≥90 % control 95 % CI low limit ≥85 % . Part 2 examine yield cancer detection MRI/biopsy among woman positive OctavaPink test result dense breast negative mammography population . Objectives : ( ) To compare yield cancer detection via MRI/biopsy among woman positive OctavaPink test versus negative OctavaPink test result . ( ii ) To estimate proportion patient positive test target population Part 3 ass sensitivity OctavaPink test enrich population woman dense breast negative mammography . Objectives : To obtain estimate sensitivity woman dense breast tissue negative mammography broadly consistent find dense breast population ( necessarily negative mammogram ) Parts 1A 1B .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Subjects dense breast tissue accord ACR criterion , ( BIRADS composition/density 3 4 ) , specific area high density behind nipple . Subject current mammography BIRADS assessment category 3 . Signed inform consent form . Additional inclusion criterion Part 1A Part 1B case Part 3 case • Subjects current biopsy/surgery proven breast cancer . Additional inclusion criterion Part 1A control , Part 1B control • Subjects current negative mammography ( BIRADS assessment category 1 2 ) . Additional inclusion criterion Part 2 • Subjects current negative mammography ( BIRADS assessment category 1 2 ) . All perform additional 1 year ( 1218 month ) mammography verify negative result . Additional inclusion criterion Part 3 • Enriched patient population Subjects current/recent ( le 12 month ) negative mammography ( BIRADS assessment category 1 2 ) . Mammography evaluation perform recruiting . Previous concurrent malignancy type except basal cell carcinoma skin , squamouscell carcinoma skin cervical carcinoma situ . Previous current ADH , ALH , LCIS . Autoimmune disorder diagnose subject . Hematological malignancy . Subjects active chemotherapy treatment chemotherapy past 6 month . Steroid treatment past 3 month . Subject undergoing immunosuppressive treatment . Subject current mammography BIRADS assessment category 3 . Pregnancy time recruitment . Doctor medical judgment prohibits participation study . Participating parallel clinical study involve drug treatment , may influence course clinical trial . Additional exclusion criterion Part 3 • Subjects current mammography BIRADS assessment 1 2 .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>cancer associate auto antibody</keyword>
	<keyword>breast cancer blood test</keyword>
</DOC>